Sequential therapy with cyclosporine and adalimumab in patients with severe plaque psoriasis: a series of five cases

被引：0
|
作者：
Gattu, S. [1 ,2 ]
Wu, J. J. [3 ]
Koo, J. Y. [2 ]
机构：
[1] Univ Calif Irvine, Irvine, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Kaiser Permanente Med Ctr, Los Angeles, CA 90034 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2009年 / 129卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
275
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [21] Early Therapy Response to Brodalumab in Patients with moderate to severe Plaque Psoriasis
    Thio, H. B.
    Hansen, J. B.
    Ghislain, P-D
    Iversen, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 64 - 65
  • [22] Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis: Subanalysis of patients with and without PsA
    Menter, MA
    Gordon, KB
    Leonardi, C
    Heffernan, MP
    Chen, DM
    RHEUMATOLOGY, 2005, 44 : I113 - I114
  • [23] Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
    Heydendael, VMR
    Spuls, PI
    Opmeer, BC
    de Borgie, CAJM
    Reitsma, JB
    Goldschmidt, WFM
    Bossuyt, PMM
    Bos, JD
    de Rie, MA
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (07): : 658 - 665
  • [24] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, Caitriona
    Crowley, Jeffrey
    Valdecantos, Wendell
    Wu, Tianshuang
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB55 - AB55
  • [25] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, C.
    Crowley, J.
    Valdecantos, W.
    Wu, T.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 21
  • [26] Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics
    Sator, P.
    Richter, L.
    Saxinger, W.
    Vasiljevic, M.
    Stingl, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (09) : 1742 - 1749
  • [27] Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis
    Mostafa, N. M.
    Nader, A. M.
    Noertersheuser, P.
    Okun, M.
    Awni, W. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 490 - 497
  • [28] Long-term safety of adalimumab in clinical trials for adult patients with moderate to severe plaque psoriasis
    Leonardi, Craig
    Papp, Kim
    Strober, Bruce
    Thaci, Diamant
    Warren, Richard B.
    Tyring, Stephen
    Arikan, Dilek
    Karunaratne, Mahinda
    Valdecantos, Wendell
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB259 - AB259
  • [29] Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without PsA.
    Menter, MA
    Gordon, KB
    Leonardi, C
    Heffernan, MP
    Chen, DM
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S611 - S612
  • [30] Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis
    Gniadecki, R.
    Leonardi, C. L.
    Gordon, K. B.
    Gu, Y.
    Geng, Z.
    Nader, A.
    Teixeira, H. D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (08) : 1297 - 1304
12345